Duchesnay Inc.

17 articles with Duchesnay Inc.

• Duchesnay USA launches three videos featuring gynecologist and menopause care specialist, Dr. Barb DePree

  8/20/2019

  Duchesnay USA, a pharmaceutical company that specializes in women's health, is pleased to announce the launch of three new videos featuring gynecologist and menopause care specialist, Dr. Barb DePree.

• Effects of Ospemifene on Genitourinary Health: Prospective Vulvar-Vestibular Photography and Direct Assessments in Post-Menopausal Women

  6/5/2019

  Duchesnay Inc., a pharmaceutical company specializing in women's health, is pleased to announce the publication of a study showing improvements in vulvovaginal health with ospemifene as assessed by prospective vulvar-vestibular photography and other direct visual assessments.

• Duchesnay USA Pledges Continued Support of the Mobile Mom Squad through Donations of its Mteryti and Mteryti folic 5 Prenatal Supplements

  3/5/2019

  The Mobile Mom Squad assists women in need in the US, as well as in several developing countries.

• Duchesnay Inc. Receives Approval of Supplemental New Drug Application (sNDA) to Add Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause, to the Indication of Osphena® (ospemifene)

  1/29/2019

  Duchesnay Inc. announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause, to the indication of Osphena® (ospemifene).

• Duchesnay USA, Maker of Osphena, Applauds Expanded Coverage for Treatments for Dyspareunia due to Menopause under Medicare Part D

  10/29/2018

  Duchesnay USA commends the clarification by the Centers for Medicare and Medicaid Services (CMS) of the statutory intent of "Prescription Drug Benefits" Section 1860D-2(e)(2)(A) of the Social Security Act.

• Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause

  10/23/2018

   Duchesnay Inc., a pharmaceutical company specializing in women's health, announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) seeking a new indication for Osphena® (ospemifene).

• Duchesnay USA Continues the Morning Sickness Conversation with Actress, Mom and Singer Jana Kramer and Beverly Hills Ob/Gyn Dr. Jay Goldberg

  10/16/2018

  Celebrity and her doctor join forces to stress the importance of communication between patients and healthcare providers

• Duchesnay Inc. to Present a Poster on Adherence, Persistence and Healthcare Costs Associated with Ospemifene at 2018 Annual Meeting of the North American Menopause Society (NAMS)

  9/14/2018

  Duchesnay Inc. announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

• Duchesnay Inc. to Present a Poster on Ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS)

  9/13/2018

  Duchesnay Inc. announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

• Duchesnay Inc. to Present a Poster on the Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness at 2018 Annual Meeting of the North American Menopause Society (NAMS)

  9/12/2018

  Duchesnay Inc. announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

• Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder

  6/7/2018

  Indicated for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients, from the age of 5 years, with overactive bladder.

• Menopausal Women Staying Silent About Painful Sex - Recent Survey Highlights Knowledge Gap About Treatment Options

  5/30/2018

  HealthyWomen along with Duchesnay USA announced the results of a survey* evaluating the experience of postmenopausal women with one of the most common and troubling symptoms of menopause: painful sex.

• Duchesnay USA Announces Launch of Bonjesta® in the United States

  4/2/2018

  Bonjesta is indicated for the treatment of nausea and vomiting of pregnancy ("NVP") in women who do not respond to conservative management.

• Mictoryl And Mictoryl Pediatric Now Available And Distributed In Canada By Duchesnay

  5/9/2017

• Duchesnay Expands Its Women's Health Product Portfolio With Acquisition Of Osphena From Shionogi

  3/13/2017

• Duchesnay Release: Company Is Pleased To Announce That Health Canada Has Granted Market Authorization For Mictoryl/Mictoryl Pediatric

  1/10/2017

• Duchesnay Obtains Exclusive Canadian Commercial Rights To Fluomizin, Indicated For The Treatment Of Vaginal Infections

  9/13/2016